Phase II clinical trial - Appareil Digestif

REGIRI (PRODIGE 58)
Appareil Digestif
Ouvert depuis le: 09.17.2021
Site: Paris
Ouvert depuis le: 02.23.2021
Site: Saint-Cloud
Public cible
Adulte
A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas
Description de l'essai

Comparative interventional prospective phase II, randomised, open-label, multicentric trial comparing the combination of regorafenib and irinotecan (REGIRI) to irinotecan alone (IRI) as second-line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.